Overall, both SGLT2-I users and GLP1-RA users appeared to suffer more from comorbidities (hypertension, hyperlipidaemia, retinopathy, neuropathy) compared to SU users, and insulin use was higher in these two groups. Here, GLP1R is linked to hypertensive disorder.